3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
The purpose of this study is evaluate the the safety, tolerability, pharmacokinetics profiles, and preliminary efficacy of 3D011-08 in subjects with advanced solid tumors.
Solid Tumor, Adult
DRUG: 3D011-08
Maximum Tolerated Dose (MTD) of3D011-08, The maximum tolerated dose as determined in Part 1 of the study will be used as the recommended dose for Part 2., 24 months|ORR, proportion of subjects in cohort 1 and cohort 2 who achieved a confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 as assessed by investigators., 24 Months|TTP, time to progression based on the PCWG3 recommendations for assessment of prostate cancer disease progression (CT/MRI, bone scan) as assessed by investigators ., 24 Months
RPTD, RP2D will be determined based on pharmacodynamics or clinical response, as well as the incidence rate and nature of the toxicities observed., 24 months|Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), 24 months|Cmax Cmax, 24 months|Css min, 24 months|Tmax, 24 months|AUC0~t、AUC0~∞, 24 months|Ctrough, 24 months|t1/2, 24 months|CL, 24 months|Vd, 24 months|ORR, proportion of subjects in part of Dose Escalation who achieved a confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 as assessed by investigators.proportion of subjects in dose expansion cohort 3 who achieved a confirmed complete response (CR) or partial response (PR) based on the PCWG3 recommendations for assessment of prostate cancer disease progression (CT/MRI, bone scan) as assessed by investigators ., 24 months|Duration of response (DoR), DoR is defined as the time from the date of first CR or PR based on RECIST v1.1 to the date of first documented progressive disease based on RECIST v1.1 or death, whichever occurs first.part1 Dose Escalation，part 2 dose expansion:Cohort 1 and Cohort 2., 24 months|Disease control rate (DCR), defined as the proportion of subjects who achieve a confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST v1.1 as assessed by investigators.Proportion of subjects in dose expansion cohort 3 who achieve a confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on the PCWG3 recommendations for assessment of prostate cancer disease progression (CT/MRI, bone scan) as assessed by investigators ., 24 months|Progression-free survival (PFS), PFS is defined as the time from the date of first study dose to disease progression based on RECIST v1.1 or death, whichever occurs first. Subjects in dose expansion cohort 3 based on the PCWG3 recommendations for assessment of prostate cancer disease progression (CT/MRI, bone scan) as assessed by investigators ., 24 months|Permeable surface area of capillary wall(PS), 24 months|the incremental Area Under Curve (iAUC), 24 months
Detailed Description: This study was initiated on February 24, 2022, at Fudan Cancer Hospital. However, noparticipants were screened or enrolled after the initiation. Due to strategic development adjustments, thecompany terminated the study on September 11. 2023.